Home › Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease
 

Keywords :   


Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease

2013-12-30 06:10:10| drugdiscoveryonline Home Page

Athersys, Inc. (Nasdaq:ATHX) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD)

Tags: europe cell drug disease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Hurricane Leslie Graphics
05.10Hurricane Leslie Forecast Discussion Number 11
05.10Hurricane Leslie Wind Speed Probabilities Number 11
05.10Hurricane Leslie Public Advisory Number 11
05.10Summary for Hurricane Leslie (AT3/AL132024)
05.10Hurricane Leslie Forecast Advisory Number 11
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 23
More »